<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387387</url>
  </required_header>
  <id_info>
    <org_study_id>VEG105424</org_study_id>
    <nct_id>NCT00387387</nct_id>
  </id_info>
  <brief_title>Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)</brief_title>
  <official_title>An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination With FOLFOX 6 or CapeOx in Subjects With Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety of treating colorectal cancer with a combination of drugs.
      The current standard treatments of FOLFOX6 or CapeOx will be give in combination with the GSK
      investigational drug pazopanib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2006</start_date>
  <completion_date type="Actual">August 14, 2009</completion_date>
  <primary_completion_date type="Actual">August 14, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1</measure>
    <time_frame>on Day 1, 14 and 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging</measure>
    <time_frame>collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Neoplasms, Colorectal</condition>
  <arm_group>
    <arm_group_label>FOLFOX 6 + Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CapeOx + Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m^2 twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases</description>
    <arm_group_label>FOLFOX 6 + Pazopanib</arm_group_label>
    <arm_group_label>CapeOx + Pazopanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX 6</intervention_name>
    <description>FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter^2[mg/m^2]), and folinic acid (400 mg/m^2), IV 5-fluorouracil bolus (400 mg/m^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m^2) infusion over 48 hours on Day 1 of every 14-day cycle.</description>
    <arm_group_label>FOLFOX 6 + Pazopanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CapeOx</intervention_name>
    <description>CapeOx treatment consists of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m^2 twice daily.</description>
    <arm_group_label>CapeOx + Pazopanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of locally advanced or metastatic colorectal cancer.

          -  No prior chemotherapy for metastatic disease.

          -  Presence of radiologically and/or clinically documented disease.

          -  Eastern Cooperative Oncology Group performance status of 0 or 1.

          -  Adequate bone marrow, hepatic, renal function, Urine Creatinine Ratio (UPC) of &lt;

          -  A female subject must not be pregnant or breast feeding.

          -  Able to swallow and retain oral medications.

        Exclusion Criteria:

          -  Has had any major surgery, chemotherapy, hormone therapy, investigational agent, or
             radiotherapy within the last 28 days

          -  Prior treatment with pazopanib, or oxaliplatin.

          -  Known contraindications to the use of oxaliplatin, capecitabine, 5-fluorouracil, or
             folinic acid.

          -  Participation in any investigational study within 28 days prior to study treatment.

          -  Women who are pregnant or lactating.

          -  Poorly controlled hypertension.

          -  A history of cardiovascular disease, arrhythmias, or significant ECG abnormalities.

          -  Any history of stroke.

          -  Current use of therapeutic warfarin.

          -  Known brain metastases.

          -  History of disease significantly affecting gastrointestinal function or major
             resection of the stomach or small bowel.

          -  Active infections or other serious illness.

          -  History of allergy to platinum compounds or heparin.

          -  Poor venous access.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyderabad, Andhra Pradesh</city>
        <zip>500482</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parel</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/VEG105424?search=study&amp;study_ids=VEG105424#rs</url>
    <description>Results for study VEG105424 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2006</study_first_submitted>
  <study_first_submitted_qc>October 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2006</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>pazopanib</keyword>
  <keyword>capecitabine</keyword>
  <keyword>CapeOx</keyword>
  <keyword>5-fluorouracil</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>combination therapy</keyword>
  <keyword>FOLFOX 6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

